Musculoskeletal News and Research RSS Feed - Musculoskeletal News and Research

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition. [More]
Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program. [More]

Intronix Technologies, Western University collaborate to develop rehabilitation devices

Intronix Technologies will be collaborating with Western University's Department of Electrical and Computer Engineering to develop technology to be incorporated into rehabilitation devices. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program. [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT). [More]
CareCore, MedSolutions complete merger agreement

CareCore, MedSolutions complete merger agreement

CareCore National, LLC and MedSolutions, Inc., two leading providers of Specialty Benefits Management (SBM) services to managed care organizations and risk-bearing provider organizations, today announced the completion of a merger that will help advance the companies' collective commitment to containing healthcare costs and achieving quality medical outcomes. [More]
Disease-associated malnutrition imposes economic burden on society

Disease-associated malnutrition imposes economic burden on society

Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition. Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition and supported by Abbott. [More]
BME announces launch of Speed Arc Nitinol Fixation System

BME announces launch of Speed Arc Nitinol Fixation System

BioMedical Enterprises announced the launch of the Speed Arc Nitinol Fixation System, the world's first superelastic shape memory fixation device that conforms to the sloping surface of the metaphyseal anatomy. This addition to the current patented BME Speed Fixation System is available in three different sizes to ensure a proper fit in varying patient anatomies. [More]
Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London. [More]
Orthopedic surgeons recommend prompt medical attention for shoulder dislocations

Orthopedic surgeons recommend prompt medical attention for shoulder dislocations

Prompt and appropriate treatment of a dislocated shoulder--when the head of the upper arm bone (humerus) is completely knocked out of the shoulder socket (glenoid)--can minimize risk for future dislocations as well as the effects of related bone, muscle and nerve injuries, according to a literature review appearing in the December issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). [More]
EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

EMA accepts new IMBRUVICA (ibrutinib) application for treatment of Waldenstrom's macroglobulinemia

Pharmacyclics, Inc.today announced the acceptance of a Type II variation application for IMBRUVICA (ibrutinib) by the European Medicines Agency. [More]
Kessler Institute provides tips to help reduce risk of injury during winter months

Kessler Institute provides tips to help reduce risk of injury during winter months

Winter appears to have arrived early, bringing with it record snowfalls and cold temperatures across the country. It also brings an increased risk for injuries. Whether shoveling snow, dealing with icy roads, or simply trying to walk on wet, slippery pavement, caution is the key word. [More]
A practical toolkit to implement coordinator-based fracture liaison services

A practical toolkit to implement coordinator-based fracture liaison services

Health authorities worldwide are coping with rising costs and disability resulting from fragility fractures in the older population. [More]
Two medical research bodies announce new research centre to tackle musculoskeletal disorders

Two medical research bodies announce new research centre to tackle musculoskeletal disorders

A major new research centre to tackle the impact of musculoskeletal disorders on people's ability to work has been announced by two leading medical research bodies. [More]
Endocrine Society issues Clinical Practice Guideline on rare bone condition

Endocrine Society issues Clinical Practice Guideline on rare bone condition

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of Paget's disease of the bone, a condition where one or more bones in the body become oversized and weak. [More]